A Global Perspective on Cardiovascular Risk Factors by Educational Level in CHD Patients: SURF CHD II

ANNA MARZÀ-FLORENSA (iD)

ILONCA VAARTJES (iD)

IAN GRAHAM (iD)

KERSTIN KLIPSTEIN-GROBUSCH (iD)

DIEDERICK E. GROBBEE (iD)

SURF CHD II COLLABORATORS

*Author affiliations can be found in the back matter of this article

ABSTRACT

Background: Clinical guidelines recommend lifestyle modifications and medication use to control cardiovascular risk factors in coronary heart disease (CHD) patients. However, risk factor control remains challenging especially in patients with lower educational level.

Objective: To assess inequalities by educational level in the secondary prevention of CHD in the Survey of Risk Factors in Coronary Heart Disease (SURF CHD II).

Methods: SURF CHD II is a cross-sectional clinical audit on secondary prevention of CHD, conducted during routine clinical visits in 29 countries. The easy-to-perform design of the survey facilitates its implementation in settings with limited resources. We reported risk factor recording, attainment of guideline-defined risk factor targets, and treatment in CHD patients. Differences by educational level in target attainment and treatment were assessed with logistic regression stratified for high- (HIC), upper middle- (UMIC), and lower middle-income (LMIC) countries.

Results: SURF CHD II included 13,884 patients from 2019 to 2022, of which 25.0% were female and 18.6% had achieved only primary school level. Risk factor recording ranged from 22.2% for waist circumference to 95.6% for smoking status, and target attainment from 15.9% for waist circumference to 78.7% for smoking. Most patients used cardioprotective medications and 50.5% attended cardiac rehabilitation.

Patients with secondary or tertiary education were more likely to meet targets for smoking, LDL cholesterol and physical activity in HICs and LMICs; for physical activity and triglycerides in UMICs; but less likely to meet targets for blood pressure in HICs and LDL <1.4mmol/L in UMICs. Higher education was positively associated with medication use and cardiac rehabilitation participation.

CONCLUSION: CHD patients generally have poor attainment of risk factor targets, but patients with a higher educational level are generally more likely to participate in cardiac rehabilitation, use medication, and meet targets.

CORRESPONDING AUTHOR:
Anna Marzà-Florensa

UMC Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands

a.marzaflorensa-3@ umcutrecht.nl

MAIN MESSAGES

1. Target attainment and participation in cardiac rehabilitation are poor in CHD patients globally.
2. Patients with higher education are more likely to meet risk factor targets, showing health inequities in secondary prevention of CHD.
3. The association between education and risk factor target attainment and treatment varies with country income level.

Marzà-Florensa et al. 2
Global Heart
DOI: 10.5334/gh.1340

INTRODUCTION

Coronary heart disease (CHD) is the leading cause of death and a major cause of disability worldwide [1]. The Global Burden of Disease Study estimates that there were 9.14 million deaths and 197 million prevalent cases of CHD in 2019 occurring predominantly in low- and middle-income countries (LMIC) [2]. Most of the burden of CHD is attributable to risk factors, many of which are potentially modifiable or controllable through lifestyle changes and medication use [2–4].

People with established CHD are at very high cardiovascular risk [5]. Therefore, risk factor control through lifestyle modification and medical therapy is fundamental to reduce risk of cardiovascular events and mortality. Clinical guidelines define targets for risk factor control in CHD patients, including smoking cessation, physical activity, weight and body composition, blood pressure, lipids, and glucose levels (Table 1) [5, 6].

RISK FACTOR	TARGET
Smoking	No smoking or cessation
Physical activity	Moderately vigorous physical activity ≥30 minutes 3–5 times/week
BMI	<25 kg/m^2
Waist circumference	<94 cm in men (<90 cm in South-East Asian men) and <80 cm in women
Blood pressure	<140/90 mmHg (<140/85 mmHg in diabetics)
LDL	<1.8 mmol/L. Stricter target: <1.4 mmol/L
non-HDL cholesterol	<2.2 mmol/L
Triglycerides	<1.7 mmol/L
Hba1c (in diabetics)	<7%

Table 1 Definition of risk factor targets.

There are several challenges in secondary prevention of CHD. Risk factor data is often not recorded in full, and thus relevant information relevant for risk factor management may be unavailable in daily practice. In terms of control, large proportions of participants do not meet risk factor targets. The most recent EUROASPIRE survey [7] reported poor levels of target attainment, despite high rates of medication use. Research on the drivers of risk factor control in patients with CHD can provide a deeper understanding of the challenges to adequate secondary prevention.

Socioeconomic circumstances, such as educational level, have shown to have an impact on risk factor control and medication use in the context of secondary prevention. Lower educational level has been linked to higher prevalence of risk factors, lower treatment levels, and higher risk of future cardiovascular events [8, 9]. Such inequalities in secondary prevention have shown to be context-dependent and may vary in different regions [10].

The Survey in Risk Factors in Coronary Heart Disease II (SURF CHD II) Study is an easy-to perform clinical audit designed to evaluate compliance with clinical guidelines in secondary prevention in daily practice. In this article, SURF CHD II data are used to assess secondary prevention of CHD and to investigate potential inequalities in risk factor management.

Specifically, we report the level of risk factor recording, guideline-defined target attainment, and treatment in CHD outpatients and investigate differences by educational level. Our results

can bring attention to potential health inequalities aimed at supporting the development of effective prevention strategies.

METHODS

STUDY DESIGN AND DATA COLLECTION

SURF CHD II consists of brief cross-sectional survey that collects data on demographics, risk factor history, risk factor measurements, medications, and participation in cardiac rehabilitation. The survey is performed as part of a clinical audit in consecutive patients with CHD attending routine outpatient visits. Centers that registered ≥100 participants were included in the present analysis.

The survey was completed from 2019 to 2022 in 105 centers located in 29 countries, including high-income countries (HICs) (Belgium, Chile, Croatia, Czech Republic, Denmark, Estonia, Greece, Hungary, Ireland, Italy, Latvia, the Netherlands, Portugal, Romania, Saudi Arabia, Spain, and the United States of America), upper middle-income countries (UMICs) (Argentina, Azerbaijan, Brazil, Kazakhstan, Libya, North Macedonia, Russia, Serbia, and Turkey), and lower middle-income countries (LMICs) (India, Indonesia, and Morocco) [11].

Patient eligibility criteria was being 18 years or older and having a previous diagnosis of CHD, including stable angina pectoris (SAP), acute coronary syndrome (ACS), percutaneous coronary intervention (PCI) (elective or acute) and/or coronary artery bypass graft (CABG) (elective or acute). SAP is defined as clinical angina with objective confirmation from ECG, ischemia on perfusion imaging, coronary angiogram showing a narrowing of 70% in at least one coronary artery.

DATA SOURCES

Data was obtained from medical records and patient interview by a physician or nurse. Participating centers in Denmark, Italy, the Netherlands, and the United States, extracted data from existing health registries of patients who were eligible for the study [12, 13]. Data was collected by use of the software RedCap [14].

ETHICAL CONSIDERATIONS

Ethical approval for this study was waived by the Medical Ethics Committee of the University Medical Center Utrecht (protocol number 17/534). Ethical approval was obtained or waived in individual participating centers prior to participation.

DATA COLLECTION AND VARIABLE DEFINITION

We registered center-level information, including the type of center (public or private) and location (urban or rural area). Routine patient data were collected on age, sex, ethnicity, educational level, and CHD diagnostic category. Ethnicity was classified as Arab, Asian, Black, Mixed, White, or other. Educational level was defined as the highest level achieved by participants and grouped as primary vs. secondary or tertiary education (including bachelor's degree or higher technical certificate). CHD Diagnostic category included stable SAP, ACS, PCI, and CABG. Information on risk factor history included admission in the hospital for a CHD-related reason in the past year, smoking history, known history of hypertension, dyslipidemia, or diabetes. The survey included questions on whether patients had participated in a cardiac rehabilitation program, and if they were using the following medications: antiplatelet drugs, beta-blockers, ACE-inhibitors, ARBs, Ca antagonists, other antihypertensives, diuretics, statins, Pcsk9-inhibitors, other lipid-lowering medications, insulin, other hypoglycemics, or nitrates. Information on height and risk factor measurements performed up to three months prior to the visit, including systolic blood pressure, diastolic blood pressure, heart rate, height, weight, and waist circumference, were collected. The following fasting blood values from up to a year before the visit were registered: total cholesterol, LDL, HDL, triglycerides, glucose, and Hba1c in diabetics.

OUTCOMES

Recording was defined as information available from interview, medical records, or laboratory results during the visit following the routine procedures. Given that one of the goals of the study was to assess risk factor recording in daily practice, health professionals were asked not to

perform additional measurements outside routine care for the purpose of the survey. If a value was missing, marked "unknown" or not available in the original data source, we considered it not to be recorded.

Risk factor targets were defined according to European Society of Cardiology (ESC) clinical guidelines [5, 6] (Table 1).

Treatment outcomes were defined as self-reported use of antiplatelet medication, antihypertensives (beta-blockers, ACE-inhibitors, ARBs, Ca antagonists, other antihypertensives), lipid-lowering medication (statins, Pcsk9-inhibitors, other lipid-lowering medications), insulin, oral hypoglycemics, and participation to cardiac rehabilitation.

DATA ANALYSIS

Categorical variables were presented as percentage of participants, and numerical variables as mean (standard deviation). We calculated the proportion of participants with recorded risk factor information, meeting risk factor targets, using medication, and participating in cardiac rehabilitation treatment by educational level.

We tested potential differences in risk factor recording, target attainment and medication use in patients with primary education compared with those with secondary or tertiary education using logistic regression adjusted by age and sex. Results are presented as odds ratios and 95% confidence intervals.

All analyses were stratified by region and performed with R Studio (version 4.0) [15]. Statistical significance was considered at a two-sided p < 0.05.

RESULTS

STUDY POPULATION

A total of 13,884 CHD patients were included in the survey, of which about half were registered in a HIC center (N = 7462). 25.0% were female, and mean age was 64.8 (sd 11.2) years. Most participants were considered ethnically white (60.9%) and Asian (31.8%). With respect to educational level, 47.0% had completed tertiary education, 34.5% secondary school, and 18.6% primary school (Table 2). Mean systolic blood pressure was 132 (sd 19.0) mmHg, mean diastolic blood pressure was 77.9 (sd 11.1) mmHg, mean BMI was 28.0 (sd 4.9) kg/m², and mean LDL cholesterol 2.24 (sd 1.1) mmol/L Supplementary Tables 1 and 2 show patient characteristics, risk factor history and measurements, fasting blood lipid and glucose levels, recording of risk factors, target attainment and treatment by HICs, UMICs, and LMICs–categorizing them by educational level. For 34.1% of the patients, data from pre-existing registries was used to complete the survey.

RISK FACTOR RECORDING

Risk factor recording was highest for smoking (95.6%) and blood pressure (92.8%), and lowest for waist circumference (22.2%). Other risk factors were recorded with variable frequency between 53.0% (HDL cholesterol) to 78.5% (LDL cholesterol) (Figure 1).

TARGET ATTAINMENT

More than three quarters (78.7%) of the study population met the target for smoking, as these either had never smoked or had quit smoking, and half (54.8%) was moderately or highly physically active. The risk factor measurement targets were met by 27.0% of the patients for BMI, 15.9% for waist circumference, and 54.3% for blood pressure. Regarding laboratory values, 40.8% had LDL levels <1.8 mmol/L, 20.8% LDL <1.4 mmol/L, 31.5% non-HDL-cholesterol <2.2 mmol/L, 65.0% triglycerides <1.7 mmol/L, and 40.5% of diabetic patients had Hba1c <7% (Figure 1).

In general, patients with a higher educational level were more likely to meet risk factor targets, though the associations between educational level and target attainment varied by risk factor and country income level. Patients with secondary or tertiary education were more likely to meet targets for smoking, physical activity, and LDL <1.8 mmol/L in HICs and LMICs, but they were less likely to meet risk the blood pressure target (in HICs). In UMICs, patients with

	(LMIC N = 2645)	UMIC (N = 3777)	HIC (N = 7462)	(TOTAL N = 13884)
Number of countries	3	9	17	29
Number of centres	11	29	65	105
Type of centre attended				
Private	1526 (57.7)	940 (24.9)	313 (4.55)	2779 (20.9)
Public	1119 (42.3)	2837 (75.1)	6561 (95.4)	10517 (79.1)
Demographics				
Mean age (SD)	62.1 (39.9)	63.0 (10.5)	66.7 (11.0)	64.8 (20.0)
Sex				
Female	502 (19.0)	1140 (30.2)	1823 (24.4)	3465 (25.0)
Ethnic Group				
Arab	346 (13.1)	102 (2.7)	123 (4.3)	571 (6.1)
Asian	2284 (86.4)	628 (16.6)	26 (0.9)	2938 (31.8)
Black	6 (0.2)	18 (0.5)	14 (0.5)	38 (0.4)
Mixed	5 (0.2)	41 (1.1)	9 (0.3)	55 (0.6)
Other	0 (0.0)	3 (0.1)	8 (0.3)	11 (0.1)
White	4 (0.2)	2981 (79.0)	2634 (93.6)	5619 (60.9)
Educational level				
Primary school	630 (24.8)	506 (16.8)	921 (16.7)	2057 (18.6)
Secondary school	964 (37.9)	1403 (46.6)	1451 (26.3)	3818 (34.5)
Tertiary/University	950 (37.3)	1100 (36.6)	3150 (57.0)	5200 (47.0)
Cardiovascular history				
Index event				
CABG	423 (16.0)	690 (18.3)	797 (15.7)	1910 (16.6)
PCI	1253 (47.4)	2197 (58.2)	2875 (56.6)	6325 (55.0)
Acute coronary syndrome	1034 (39.1)	1462 (38.7)	4128 (55.3)	6624 (47.7)
Stable angina pectoris	855 (32.3)	1539 (40.7)	2146 (28.8)	4540 (32.7)
Family history premature CVD	288 (10.9)	1184 (31.4)	819 (29.0)	2291 (24.8)
Risk factor history				
Hypertension	1359 (51.4)	3109 (82.3)	3162 (65.7)	7630 (67.9)
Dyslipidemia	1234 (46.7)	1974 (52.3)	3163 (67.5)	6371 (57.4)
Diabetes	1129 (29.2)	1136 (42.9)	1294 (34.3)	3559 (34.6)
Smoking				
Current	423 (16.3)	861 (23.7)	1541 (21.9)	2825 (21.3)
Former	442 (17.0)	1112 (30.6)	3129 (44.4)	4683 (35.3)
Never	1736 (66.7)	1661 (45.7)	2373 (33.7)	5770 (43.5)
Physical activity < 30 minutes 3–5 times/week	979 (38.0)	1690 (52.9)	1640 (43.6)	4309 (45.2)
Moderate	1259 (48.8)	1037 (32.5)	1451 (38.5)	3747 (39.3)
Physical activity > 30 minutes 3–5 times/week	340 (13.2)	465 (14.6)	673 (17.9)	1478 (15.5)
Risk factor levels (mean (SD))				
Systolic BP (mmHg) mean (SD)	128 (20.2)	134 (20.3)	132 (17.7)	132 (19.0)
Diastolic BP (mmHg) mean (SD)	75.8 (11.3)	80.7 (11.4)	77.2 (10.6)	77.9 (11.1)

(Contd.)

Table 2 Characteristics of the study population by country income group.

Results are indicated in number of participants (%) unless indicated. HICs: high-income counties, UMICs: upper-middle-income countries, LMICs: lower-middle income countries, CABG: Coronary Artery Bypass Graft, PCI: Percutaneous Coronary Intervention, CVD: cardiovascular disease.

|	(LMIC N = 2645)	UMIC (N = 3777)	HIC (N = 7462)	(TOTAL N = 13884)
Heart rate (bpm) mean (SD)	77.8 (13.6)	73.7 (12.9)	68.9 (12.2)	73.1 (13.3)
BMI (kg/m^2) mean (SD)	26.5 (4.5)	28.7 (4.9)	28.2 (5.0)	28.0 (4.9)
Waist circumference (cm) mean (SD)	90.5 (15.4)	99.2 (12.7)	103 (13.1)	100 (13.7)
Total cholesterol (mmol/l) mean (SD)	3.86 (1.2)	4.70 (1.4)	3.98 (1.4)	4.19 (1.4)
LDL cholesterol (mmol/l) mean (SD)	2.15 (1.1)	2.79 (1.2)	2.06 (1.0)	2.24 (1.1)
HDL cholesterol (mmol/l) mean (SD)	1.11 (0.4)	1.19 (0.4)	1.22 (0.4)	1.18 (0.4)
Tryglicerides (mmol/l) mean (SD)	3.74 (1.9)	2.44 (2.0)	2.76 (1.9)	2.92 (2.0)
Fasting glucose (mmol/l) mean (SD)	7.63 (3.5)	6.78 (2.8)	6.44 (2.2)	6.88 (2.9)
HbA1C (%)	7.97 (1.7)	7.74 (1.7)	8.94 (11.1)	8.23 (6.5)

Figure 1 Percentage of participants **(A)** meeting risk factor targets, **(B)** with information recorded on risk factors, and **(C)** reporting to use medication and participate in cardiac rehabilitation. Risk factor targets are defined as: no smoking or smoking cessation, Moderately vigorous physical activity at least 30 minutes 3–5 times/week, BMI <25 kg/m^2, waist circumference <94 cm in men (<90 cm in South-East Asian men) and <80 cm in women, blood pressure <140/90 mmHg (<140/85 mmHg in diabetics), LDL <1.8 mmol/L, LDL <1.4 mmol/L, non-HDL cholesterol <2.2 mmol/L, triglycerides <1.7 mmol/L, and Hba1c (in diabetic patients) <7%. Results on Hba1c recording, target attainment, oral hypoglicemics, and insulin are calculated among diabetic patients.

secondary or tertiary education were more likely to meet physical activity and triglycerides targets; yet, they were less likely to have LDL <1.4 mmol/L (Table 3).

TREATMENT

Most patients were using antiplatelet (92.6%), antihypertensive (94.2%), and lipid-lowering (89.3%) medication. Half of the study participants participated in a cardiac rehabilitation program (50.5%), with important variation by country-income status: participation was 74.5% in HICs, 25.7% in UMICs, and 21.8% in LMICs (Figure 1, **Supplementary Table 1**).

Higher educational level was positively associated with the use of antiplatelet medication and antihypertensives (HICs) and lipid-lowering drugs (HICs and LMICs), but negatively associated with and insulin among diabetics and lipid-lowering drugs in UMICs. Higher education was strongly associated with participation in cardiac rehabilitation in HICs and UMICs (Table 3).

	HIC	UMIC	LMIC
Target attainment[a]			
Never or former smoking	1.71 (1.43–2.04)	1.14 (0.88–1.47)	1.99 (1.53–2.59)
Physical activity	1.94 (1.59–2.35)	2.48 (1.96–3.14)	1.75 (1.41–2.13)
BMI	1.06 (0.84–1.34)	1.10 (0.81–1.51)	0.89 (0.71–1.11)
Waist circumference	1.30 (0.82–2.12)	0.63 (0.37–1.10)	0.86 (0.53–1.40)
Blood pressure	0.64 (0.53–0.77)	1.02 (0.83–1.27)	0.92 (0.75–1.14)
non-HDL Cholesterol	1.01 (0.79–1.30)	0.92 (0.64–1.35)	1.19 (0.94–1.49)
LDL 1.8	1.23 (1.05–1.45)	0.74 (0.55–1.01)	1.30 (1.04–1.63)
LDL 1.4	0.94 (0.78–1.13)	0.65 (0.44–1.00)[c]	1.21 (0.93–1.58)
Triglycerides	0.85 (0.66–1.09)	1.32 (1.01–1.72)	1.14 (0.91–1.44)
Hba1c[b]	0.82 (0.45–1.36)	0.89 (0.53–1.50)	1.20 (0.80–1.82)
Treatment			
Antiplatelets	1.66 (1.22–2.23)	1.285 (0.97–1.69)	1.5 (0.94–2.35)
Antihypertensives	1.995 (1.32–2.96)	0.72 (0.48–1.05)	1.03 (0.64–1.63)
Lipid-lowering	1.424 (1.05–1.90)	0.62 (0.48–0.79	1.75 (1.20–2.55)
Oral hypoglicemics	1.43 (0.94–2.16)	1.08 (0.78–1.49)	1.26 (0.92–1.72)
Insulin[b]	1.10 (0.70–1.73)	0.43 (0.30–0.61)	0.88 (0.59–1.34)
Cardiac rehabilitation[b]	2.47 (2.10–2.91)	4.89 (3.44–7.18)	1.24 (0.99–1.56)

Table 3 Results multivariable analysis showing odds ratios for achieving risk factor targets, being on medication or participating in cardiac rehabilitation, and secondary or tertiary educational level compared to primary education.

Results are expressed in odds ratios (95% confidence intervals) of achieving risk factor targets and being on medication or participating in cardiac rehabilitation, if having secondary or tertiary education compared to primary education, adjusted by age, sex, and type of center (public or private). [a] Risk factor targets are defined as: no smoking or smoking cessation, Moderately vigorous physical activity at least 30 minutes 3–5 times/week, BMI <25 kg/m², waist circumference <94 cm in men (<90 cm in South-East Asian men) and <80 cm in women, blood pressure <140/90 mmHg (<140/85 mmHg in diabetics), LDL <1.8 mmol/L, LDL <1.4 mmol/L, non-HDL cholesterol <2.2 mmol/L, triglycerides <1.7 mmol/L, and Hba1c (in diabetic patients) <7%. [b] Estimates are calculated among diabetic patients. [c] 97.5% CI = 0.999.

SENSITIVITY ANALYSIS

Levels of risk factor recording for some variables, such as physical activity, BMI, and blood lipids, were lower among patients whose data was collected through pre-existing sources as compared to interview (**Supplementary Table 3**). Otherwise, no major differences by data collection source were observed in patients' characteristics, attainment of risk factors, treatment, or the associations between educational level and target attainment or treatment. Similarly, sensitivity analysis by CHD diagnostic category showed no major differences in study outcomes (**Supplementary File 2**).

DISCUSSION

SUMMARY OF MAIN FINDINGS

In our study of 13,884 patients with CHD from 29 countries in Europe, the Middle-East, North- and South America, and Asia, we observed reasonable recording of most risk factors and high use of most medication classes, but poor attainment of risk factor targets and participation in cardiac rehabilitation. Patients with higher education are generally more likely to meet risk factor targets, to receive medical treatment, and to participate in cardiac rehabilitation, although these associations varied in different country income groups.

RECORDING

Our findings show that blood pressure and smoking were registered in almost all patients; however, recording for other risk factors such as blood lipids, Hba1c, and BMI were modest, and very low for waist circumference. Previous studies similarly found satisfactory recording of blood pressure in primary care [16, 17], and of blood pressure and smoking in secondary prevention [18], reporting incomplete data on other risk factors too. We also observed lower risk factor recording

for some variables in data collected from pre-existing sources as compared to interviews, which can be partly explained by the structure of these data sources as some variables are not collected by design. Overall, the low level of recording observed is cause for concern because risk factor recording is a key step for efficient counseling, adaptation to therapy, and follow-up [16–18].

TARGET ATTAINMENT

Our results show poor levels of target attainment in secondary prevention, especially for weight-related risk factors and blood lipids. These findings are in line with previous studies [7, 18–20], and these highlight the need to improve risk factor control in CHD patients.

Patients with higher educational level were generally more likely to meet risk factor targets, although these associations varied by country income group and risk factor. A higher educational level was associated with meeting the target for smoking in all country-income groups, while a negative association was observed for waist circumference and LDL targets in UMICs, and for BMI targets in LMICs.

A positive association between educational level and risk factor target attainment has been reported in previous studies [8, 20]. In EUROASPIRE V, CHD patients with primary or secondary education were less likely to meet risk factor targets for most cardiovascular risk factors compared to patients with tertiary education [8]. Higher educational level were associated with achieving physical activity targets in Swedish CHD patients [20], and with having a healthy diet and not smoking in participants of the community-based PURE Study [10].

The differences in risk factor target attainment by educational level shown in our results could be partly attributed to risk factor awareness and health literacy. Patients with a higher educational level are more likely to be aware of their risk factors, measured levels, and targets [8], as well as to have more extensive health literacy [21, 22]. Patient's awareness of their risk factor profile is a key to motivate lifestyle changes, and it is associated with prevention-seeking behaviors and risk factor control [23, 24]. Adequate health literacy allows patients to understand health-related information and make informed decisions [25, 26]. Knowledge on risk factors has been associated with improved health behaviors [23], and results from a systematic review [25] show that patients with low health literacy have less knowledge on preventive methods and use of preventive health services.

Differences in care provision by public and private centers can contribute to the differential target attainment by educational level. Therefore, we included the private or public organization of participating centers in our models. Most SURF CHD II patients in HICs, with generally strong public healthcare systems and universal health coverage [27], attended public centers regardless of their educational level, whereas most patients with higher education attended private centers in LMICs (**Supplementary Table 2**). Previous studies conducted in Brazil showed that CHD patients treated in the private system were more likely to meet the physical activity target, and to use and adhere to guideline-recommended medications [28, 29] suggesting that patients using private care in such settings may have better access to medications [30], as well as more frequent healthcare utilization [31], and thus a more effective management of risk factors. As provision of services in public and private health systems varies greatly by country, future specific analysis should allow for in-depth research on this topic. Variations in target attainment by country income group (such as in BMI and waist circumference), could further be influenced by the differential ethnic distribution; for example, the majority of participants in LMICs were Asian, while most patients in HICs were white.

Differences in risk factors at baseline by educational level could also play a role in the association between educational level and target attainment. In our data, for example, the proportion of patients who never smoked is similar across educational level groups, while the proportion of patients who quit or were current smokers varies by educational level (**Supplementary Table 2**). However, changes in risk factors could not be assessed due to the cross-sectional design of the study.

MEDICATION AND CARDIAC REHABILITATION

We observe overall high levels of usage of all medication classes in SURF CHD II, in line with the previous surveys in secondary prevention [18, 32]. Patients with secondary or tertiary education

were more likely to use antiplatelet, antihypertensive, and lipid-lowering medications in HICs, and lipid-lowering medication and oral hypoglycemics in LMICs, while a more inconsistent pattern was observed in UMICs. Although these differences were significant, in many cases these differences were small; for example, 96.7% vs. 95.2% for antihypertensives, and 94.6% vs 91.9% for lipid-lowering drugs in HICs (**Supplementary Table 1**). Ohm et al. described higher statin use among higher educated patients [20], while the PURE study described higher medication use among lower educated patients in HICs [10], and the most recent EUROASPIRE survey reported no differences in secondary prevention medication use by educational level [8].

Half of the participants in SURF CHD II reported to have participated in a cardiac rehabilitation program, which is a higher estimate than the one reported in Euroaspire IV [33]. Cardiac rehabilitation has proven to be effective in reducing morbidity and mortality risk in coronary patients, and a comprehensive cardiac rehabilitation program has class 1 A recommendation by clinical guidelines [5, 34]. Attendance to cardiac rehabilitation was remarkably lower in UMICs (25.7%) and LMICs (21.8%) compared to HICs (74.5%).

Patients with primary educational level were less likely to participate in cardiac rehabilitation in HICs and UMICs. Accordingly, previous studies in Europe and the US have shown lower referral rates for cardiac rehabilitation [35], and lower participation attendance in patients with a lower educational level compared to those with higher education. [33, 36]. Barriers to cardiac rehabilitation, like lack of availability or access to programs, low awareness on the program benefits, large distances to health centers, out-of-pocket payments, and disadvantages and costs caused by absence from work [20, 37], may impact patients with a lower educational level disproportionately. Cardiac rehabilitation programs are available only in 54.7% of countries [38], and, especially in UMICs and LMICs, there are financial barriers associated with coverage for cardiac rehabilitation [39, 40].

Our results highlight that even with high levels of medication use, risk factor target attainment remained poor. Further research on the use of drug combinations, dose adequacy, and adherence, might help to clarify the difficulties controlling risk factors. The fact that higher educated participants were generally more likely to use medication and to attend cardiac rehabilitation could partly contribute to the higher levels of risk factor target attainment among patients with secondary or tertiary education.

IMPLICATIONS AND FUTURE RESEARCH

Our results emphasize the importance of addressing barriers to risk factor target attainment and cardiac rehabilitation that are specific to people with lower educational levels. This could be adapted communication strategies, intensive and personalized follow-up to improve target attainment, and promotion of access to affordable and (partly) remote cardiac rehabilitation programs.

One of the main findings of our study is that the associations between educational level and risk factor target attainment and treatment are heterogeneous. Therefore, future studies should investigate local circumstances that hinder risk factor target attainment and treatment in daily practice, with attention to patients' educational attainment. The resulting insights may support the design of efficient preventive strategies at regional, country, and center level.

STRENGTHS AND LIMITATIONS

Our study is among the first to investigate risk factor recording, target attainment, and treatment in secondary prevention by educational level and country income group in a clinical setting. Research on risk factor recording is scarce, especially for secondary prevention, and we present results for registration of risk factor information in daily practice. The simplicity of the SURF CHD II audit allows registration of the most relevant information of risk factors, while requiring little time and few financial resources. This also facilitates participation of smaller units and low-resource areas, which often have been underrepresented in research, despite high levels of cardiovascular risk [41]. Therefore, SURF CHD provides real-world evidence on secondary prevention globally, and its large sample size allows for context specific analysis. SURF CHD II provides a useful tool for health centers of any level to assess secondary prevention outcomes in their specific context and apply and evaluate tailor-made prevention strategies.

This study has some limitations. First, centers were not randomly selected, although diversity among the included centers was promoted. Second, health professionals were instructed to only register information collected during routine visits, but it is possible that some additional measurements were performed. These factors may have resulted in some overestimation of the risk factor recording, target attainment, and treatment levels in our results. Additionally, the high level of missing values for BMI, waist circumference, and lipid measurements, may influence the recording and target attainment estimates. As educational level was not registered in some centers, we were, unfortunately, not able to include these participants in the main analysis. Although the simplicity of SURF CHD II is one of its main strengths, it inevitably limits the information that can be collected for study participants, including data that might have provided more insights into the results, like in-depth information on risk factors, sex-specific risk factors, statin intensity, adherence to medication, or time since index event.

CONCLUSION

The SURF CHD II study conducted in 13,884 CHD patients from 29 HICs, UMICs, and LMICs provides global, real-world evidence on secondary prevention of CHD. SURF CHD II shows poor attainment of risk factor targets and participation in cardiac rehabilitation, highlighting the urge for improvement in secondary prevention of CHD in daily practice.

The association between educational level and risk factor target attainment is heterogeneous and complex. Further research into health inequalities on secondary prevention outcomes in different contexts might support the identification of barriers to secondary prevention and the application of more effective preventive strategies, which are most needed.

DATA ACCESSIBILITY STATEMENT

Data is available upon reasonable request to co-authors.

ADDITIONAL FILES

The additional files for this article can be found as follows:

- **Supplementary File 1.** Supplementary Figure 1, Supplementary Tables 1 to 3. DOI: https://doi.org/10.5334/gh.1340.s1
- **Supplementary File 2.** Sensitivity Analysis. DOI: https://doi.org/10.5334/gh.1340.s2

ACKNOWLEDGEMENTS

FUNDING INFORMATION

COMPETING INTERESTS

The authors have no competing interests to declare.

AUTHOR CONTRIBUTIONS

AMF conducted data and project management, performed the formal analysis, and wrote the original draft. AMF, KKG and IV contributed to the conceptualization of this work. IG, DEG, IV, and KKG contributed to the design and set up of the study. SURF CHD II contributors collected data and coordinated the participation of centres at national level. All co-authors critically reviewed and edited the manuscript and approved the final version.

AUTHOR INFORMATION

SURF CHD Collaborators

Marina Joseph, Yanina Castillo Costa	Socieded Argentina de Cardiología, Buenos Aires
Nicolás Esteybar Enrique	Counsel of Cardioecology and Healthy Habits Sociedad Argentina de Cardiología, Mar del Plata, Argentina
Rahima Gabulova	Azerbaijan Medical University, Educational Therapeutic Clinic, Baku, Azerbaijan
Mahluga Isaveva	Scientific Research Institute for Cardiology, Baku, Azerbaijan
Farid Alivev	Baku Health Centre, Baku, Azerbaijan
Uzeyir Rahimov	Baku Medical Plaza, Baku, Azerbaijan
Galib Imanov	Azerbaijan Medical University, Educational Surgical Clinic, Baku, Azerbaijan
Firdovsi Ibrahimov	Central Clinic Hospital, Baku, Azerbaijan
Zarbaliyeva Naila	Ganja City United Hospital, Ganja, Azerbaijan
Rashad Abasov	ER Medical, Khachmaz, Azerbaijan
Paul Dendale, Anre Jassen	Jessa Hospital-Hartcentrum, Hasselt, Belgium
Johan De Sutter	AZ Maria Middelares Cardiologie, Gent, Belgium
Sofie Cuypers	Hartcentrum OLV ziekenhuis, Aalst, Belgium
Dalton Precoma	Sociedade Hospitalar Angelina Caron, Campina Grande do Sul, Brazil
Luiz Ritt	Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil
Mario Claudio Soares Sturzeneker	Wallace Thadeu de Mello e Silva Regional University Hospital, Brazil
Conrado Roberto Hoffmann Filho	Street Blumenau, 294 Centro, Joinville SC, Brazil
Maria Teresa Lira	Hospital Clínico Fuerza Aérea de Chile, Santiago, Chile
Michal Varablik, Eva Tumova	Centre of Preventive Cardiology, 3th Department of internal medicine, 1st Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic
Jaromir Ozana	Department of Exercise Medicine and Cardiovascular Rehabilitation, University Hospital Olomouc, Czech Republic
Ann Bovin	Danish Society of Cardiology, Copenhagen, Denmark
Margus Viigimaa	North Estonia Medical Centre, Tallinn University of Technology, Tallin, Estonia
Konstantinos Tsioufis, Ageliki Laina	Cardiology Department, Hippokration General Hospital, Athens, Greece
Zacharoulis Achilles, Fotios Toulgaridis	General Hospital of Athens "Evangelismos", Athens, Greece
Elias Sanidas	LAIKO General Hospital, Athens, Greece
Zeljko Reiner	Polish Mother's Memorial Hospital Research Institute, Lodz, Poland & University Hospital Center, Zagreb, Croatia
Marijana Gulin, Antonijo Bejúić	County Hospital Sibenik, Croatia
Darko Duplančić	University Hospital, Split, Croatia
Jozica Šikić	University Hospital Sveti Duh, Croatia
Eszter Szabados	Ist Department of Medicine, Division of Preventive Cardiology and Rehabilitation, University of Pécs, Medical School, Pécs, Hungary
Badai Bhatara Tiksnadi	Hasan Sadikin General Hospital, Bandung, West Java, Indonesia
Bill McEvoy	University Hospital Galway, Galway, Ireland
Anne Reynolds, David Moore	Tallaght University, Hospital Cardiology clinic, Dublin, Ireland
Declan Spelman	South Tipperary General Hospital, Tipperary, Ireland
Raman Puri, Rashmi Nanda	Cardiac Care Centre, New Delhi, India
Nagaraj Desai	Namana Medical Centre, Bengaluru, India

SURF CHD Collaborators

Prabhakar Dorairaj	Ashwin Clinic, Annanagar, India
S. S. Iyengar, Sumitra Lakshmana	Manipal Hospital, Bangalore, India
Ajay Kumar Pandey	Galaxy Hospital, Mahmoorganj, India
Akshyaya Pradhan	King George's Medical University, Lucknow, India
Kunal Mahajan	Himachal Heart Institute, Chhanwari, India
Pompilio Faggiano	Ospedali Riuniti, Brescia, Italy
P. Zarcone	Policlinico P. Giccone, Palermo, Italy
Maurizio G Abrignani	S Antonio Abate Hospital of Trapani, O.U. of Cardiology, Trapani, Italy
Makhanov Daniyar	Central Clinical Hospital, Almaty, Kazakhstan
Kairat Davletov	Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan
Kuatbek Toleubekov, Olga Visternichan	Cardiorehabilitation Center "Tulpar", Karaganda Medical University, Karaganda, Kazakhstan
Alibek Mereke	City Policlinic № 32, Al Farabi Kazakh National University, Almaty, Kazakhstan
Anar Dushpanova	City Policlinic № 32, Al Farabi Kazakh National University, Almaty, Kazakhstan; Scuola Superiore Sant'Anna, Pisa, Italy
Bekbolat Zholdin, Zhanat Timirbayev	Medical Center of West Kazakhstan Marat Ospanov Medical University, Zhanakonys, Kazakhstan
Gulmira Derbissalina	Astana Medical University, University hospital, Astana, Kazakhstan
Daulet K. Aldyngurov	Department of Science and Human resource, Ministry of Healthcare, Kazakhstan
Ayan Myssayev	Cardiological Center of Pavlodar region, Department of Science and Human resourse, Ministry of Healthcare, Kazakhstan
Alma Nurtazina	Cardiological Center of Pavlodar region, Semey Medical University, Semey, Kazakhstan
Zhanna Romanova, Sundetgali Kalmakhanov	City polyclinic № 5, Al Farabi Kazakh National University, Almaty, Kazakhstan
Iveta Mintale	Latvian Center of Cardiology, Riga, Latvia
Omar Msalam	Libyan Cardiac Society, Tripoli, Libya
Emhemed Ehemmali	Misrata Heart & Cardiovascular Center, Misrata, Libya
Alami Mohamed	Cabinet Cardiologie ALAMI, Casablanca, Morocco
Najat Mouine	Cardiology Centre, Mohammed V Military Hospital, Rabat, Morocco
Tazi Mezalek Amale	Hopital Universitaire Cheikh Zaid, Rabat, Morocco
Aida Soufiani, Zineb Agoumy, Houda Bachri, Imad Massri	Ligue Nationale de cardiologie, Rabat, Morocco
Irena Mitevska	University Cardiology Clinic, Skopje, North Macedonia
Saskia Haitjema, Mark de Groot	Utrecht Patient Oriented Database (UPOD), Central Diagnostic Laboratory, Division of Laboratory, Pharmacy, and Biogenetics, University Medical Center Utrecht, Utrecht University, Utrecht
Ana Abreu	Hospital Universitário Santa Maria, IMPSP, ISAMB, Faculty of Medicine of University of Lisbon, Lisbon
Svetlana Mosterou, Dan Gaita	Institute for Cardiovascular Diseases, Timisoara, Romania
Nana Pogosova	National Medical Research Center of Cardiology, Preventive Cardiology Laboratory, Moscow, Russia
Marat V. Ezhov	Federal State Budget Institution, National Cardiology Research Centre of Ministry of Healthcare of Russian Federation, Moscow, Russia
Abdulhalim Kinsara	Ministry of National Guard health affairs. King Saud bin Abdulaziz University for Health Sciences, COM-WR. King Abdullah International Research Center, Jeddah, Saudi Arabia

(Contd.)

SURF CHD Collaborators	
Ivana Burazor	Cardiology, Institute for rehabilitation; Cardiology, Institute for rehabilitation, and University of Belgrade – Faculty of Medicine, Institute for Cardiovascular Diseases 'Dedinje', Belgrade, Serbia
Vojislav Giga	Cardiology Clinic, Clinical Center of Serbia, Belgrade, Serbia
Hector Bueno	Hospital 12 de Octubre, Madrid, and Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain
Regina Dalmau	University Hospital la Paz, Madrid, Spain
Ana García-Barrios	Hospital General Universitario Dr. Balmis, Alicante, Spain
Jose Antonio Alarcon Duque, Joana Reparaz Mendinueta	Hospital Universitario Donostia/OSI Donostialdea, Donostia, Spain
Meral Kayikcioglu	Ege University Medical School Cardiology Department, Ege University Tip Fak Kardivoloii AD Bornova Izmir, Turkey
Lale Tokgozoglu	Hacettepe University, Department of Cardiology, Ankara, Turkey
Emre Aslanger	Basaksehir Pine and Sakura City Hospital, Istanbul, Turkey
Ayca Turer Cabbar	Yeditepe Univerisity Hospital, Istanbul, Turkey
Samuel Kim, Caleb Self, Dolores Reynolds, Sabrina Rose, Pretti Singh	Weil Cornell Medicine, New York, United States

AUTHOR AFFILIATIONS

Anna Marzà-Florensa orcid.org/0000-0003-0338-4292
Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

Ilonca Vaartjes orcid.org/0000-0002-9951-5164
Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

Ian Graham orcid.org/0000-0002-0979-4674
Trinity College, Dublin, Ireland

Kerstin Klipstein-Grobusch orcid.org/0000-0002-5462-9889
Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; Division of Epidemiology and Biostatistics, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Diederick. E Grobbee orcid.org/0000-0003-4472-4468
Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

SURF CHD II collaborators

REFERENCES

1. **Vos T, Lim SS, Abbafati C,** et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet.* 2020; 396: 1204–22. DOI: https://doi.org/10.1016/S0140-6736(20)30925-9

2. **Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM,** et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: Update from the GBD 2019 Study. *Journal of the American College of Cardiology.* Elsevier. 2020; 76: 2982–3021.

3. **Murray CJL, Aravkin AY, Zheng P, Abbafati C, Abbas KM, Abbasi-Kangevari M,** et al. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. *The Lancet.* 2020; 396(10258): 1223–1249. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673620307522.

4. **Wang C, Sun Y, Jiang D, Wang C, Liu S.** Risk-attributable burden of ischemic heart disease in 137 low-and middle-income countries from 2000 to 2019. *J Am Heart Assoc.* 2021; 10(19): e021024. DOI: https://doi.org/10.1161/JAHA.121.021024

5. **Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M,** et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *European Heart Journal.* Oxford University Press. 2021; 42: 3227–3337.

6. **Neumann FJ, Sechtem U, Banning AP, Bonaros N, Bueno H, Bugiardini R,** et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *European Heart Journal. Oxford University Press.* 2020; 41: 407–477.

7.　**Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D,** et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. *Eur J Prev Cardiol.* 2019; 26(8): 824–835. DOI: https://doi.org/10.1177/2047487318825350

8.　**Bruthans J, Mayer O, De Bacquer D, De Smedt D, Reiner Z, Kotseva K,** et al. Educational level and risk profile and risk control in patients with coronary heart disease. *Eur J Prev Cardiol.* 2016; 23(8): 881–890. DOI: https://doi.org/10.1177/2047487315601078

9.　**Schultz WM, Kelli HM, Lisko JC, Varghese T, Shen J, Sandesara P,** et al. Socioeconomic status and cardiovascular outcomes: Challenges and interventions. *Circulation.* 2018; 137(20): 2166–2178. DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.029652

10.　**Rosengren A, Smyth A, Rangarajan S, Ramasundarahettige C, Bangdiwala SI, AlHabib KF,** et al. Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study. *Lancet Glob Health.* 2019; 7(6): e748–e760. DOI: https://doi.org/10.1016/S2214-109X(19)30045-2

11.　**The World Bank Group.** World Bank Country and Lending Groups 2023. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups.

12.　**Zwisler AD, Rossau HK, Nakano A, Foghmar S, Eichhorst R, Prescott E,** et al. The Danish cardiac rehabilitation database. Clinical Epidemiology. *Dove Medical Press.* 2016; 8: 451–456. DOI: https://doi.org/10.2147/CLEP.S99502

13.　**Ten Berg MJ, Huisman A, Van Den Bemt PMLA, Schobben AFAM, Egberts ACG, Van Solinge WW.** Linking laboratory and medication data: New opportunities for pharmacoepidemiological research. *Clinical Chemistry and Laboratory Medicine.* 2007; 45: 13–19. DOI: https://doi.org/10.1515/CCLM.2007.009

14.　**Harris PA, Taylor R, Thielke R, Payne J, Gonzalez NJGC.** Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* 2009; 42(2): 377–381. DOI: https://doi.org/10.1016/j.jbi.2008.08.010

15.　**RStudio Team.** *RStudio: Integrated Development for R. RStudio, Inc.,* Boston, MA. 2019. Available from http://www.rstudio.com/.

16.　**Giorda CB, Guida P, Avogaro A, Cortese C, Mureddu GF, Corsini A,** et al. Association of physicians' accuracy in recording with quality of care in cardiovascular medicine. *European Journal of Cardiovascular Prevention and Rehabilitation.* 2009; 16(6): 722–728. DOI: https://doi.org/10.1097/HJR.0b013e3283317c3f

17.　**Ludt S, Petek D, Laux G, Van Lieshout J, Campbell SM, Künzi B,** et al. Recording of risk-factors and lifestyle counselling in patients at high risk for cardiovascular diseases in European primary care. *Eur J Prev Cardiol.* 2012; 19(2): 258–266. DOI: https://doi.org/10.1177/1741826711400510

18.　**Zhao M, Cooney MT, Klipstein-Grobusch K, Vaartjes I, De Bacquer D, De Sutter J,** et al. Simplifying the audit of risk factor recording and control: A report from an international study in 11 countries. *Eur J Prev Cardiol.* 2016; 23(11): 1202–1210. DOI: https://doi.org/10.1177/2047487316647827

19.　**Vedin O, Hagström E, Stewart R, Brown R, Krug-Gourley S, Davies R,** et al. Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: Baseline results from the STABILITY study. *Eur J Prev Cardiol.* 2013; 20(4): 678–685. DOI: https://doi.org/10.1177/2047487312444995

20.　**Ohm J, Skoglund PH, Häbel H, Sundström J, Hambraeus K, Jernberg T,** et al. Association of socioeconomic status with risk factor target achievements and use of secondary prevention after myocardial infarction. *JAMA Netw Open.* 2021; 4(3): 1–14. DOI: https://doi.org/10.1001/jamanetworkopen.2021.1129

21.　**Ghisi GL de M, Chaves GS da S, Britto RR, Oh P.** Health literacy and coronary artery disease: A systematic review. Patient Education and Counseling. *Elsevier Ireland.* 2018; 101: 177–184. DOI: https://doi.org/10.1016/j.pec.2017.09.002

22.　**Tchicaya A, Braun M, Lorentz N, Delagardelle C, Beissel J, Wagner DR.** Social inequality in awareness of cardiovascular risk factors in patients undergoing coronary angiography. *Eur J Prev Cardiol.* 2013; 20(5): 872–879. DOI: https://doi.org/10.1177/2047487312446123

23.　**Tchicaya A, Lorentz N, Demarest S, Beissel J.** Persistence of socioeconomic inequalities in the knowledge of cardiovascular risk factors five years after coronary angiography. *European Journal of Cardiovascular Nursing.* 2018; 17(2): 136–147. DOI: https://doi.org/10.1177/1474515117720789

24.　**Jankowski P, Kawecka-Jaszcz K, Bilo G, Pajak A.** Determinants of poor hypertension management in patients with ischaemic heart disease. *Blood Press.* 2005; 14(5): 284–292. DOI: https://doi.org/10.1080/08037050500239962

25.　**Peltzer S, Hellstern M, Genske A, Jünger S, Woopen C, Albus C.** Health literacy in persons at risk of and patients with coronary heart disease: A systematic review. *Social Science and Medicine.* Elsevier. 2020; 245: 112711. DOI: https://doi.org/10.1016/j.socscimed.2019.112711

26. **Sørensen K, Pelikan JM, Röthlin F, Ganahl K, Slonska Z, Doyle G,** et al. Health literacy in Europe: comparative results of the European health literacy survey (HLS-EU). *The European Journal of Public Health.* 2015; 25(6): 1053–1058. DOI: https://doi.org/10.1093/eurpub/ckv043

27. **World Health Organization, World Bank.** Tracking Universal Health Coverage: 2021 Global Monitoring Report. 2021.

28. **Birk MG, Carvalho Goulart A, Lotufo PA, Martins Benseñor I.** Secondary prevention of coronary heart disease: A cross-sectional analysis on the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). *Sao Paulo Med J.* 2019; 137(3): 223–233. DOI: https://doi.org/10.1590/1516-3180.2018.0531140319

29. **de Carvalho Costa IMNB, Silva DG da, Oliveira JLM, Silva JRS, Pereira LMC, Alves LVS,** et al. Adherence to secondary prevention measures after acute coronary syndrome in patients associated exclusively with the public and private healthcare systems in Brazil. *Prev Med Rep.* 2022; 29: 101973. DOI: https://doi.org/10.2139/ssrn.4094242

30. **Harrison MA, Marfo AFA, Annan A, Ankrah DNA.** Access to cardiovascular medicines in low- and middle-income countries: a mini review. Global Health Research and Policy. *BioMed Central.* 2023; 8(1): 17. DOI: https://doi.org/10.1186/s41256-023-00301-6

31. **Yang JM, Lee S bin, Kim Y ji, Chon D young, Moon JY, Kim JH.** Association between private health insurance and medical use by linking subjective health and chronic diseases. *Medicine.* 2022; 101(32): e29865. DOI: https://doi.org/10.1097/MD.0000000000029865

32. **De Smedt D, De Backer T, Petrovic M, De Backer G, Wood D, Kotseva K,** et al. Chronic medication intake in patients with stable coronary heart disease across Europe: Evidence from the daily clinical practice. Results from the ESC EORP European Survey of Cardiovascular Disease Prevention and Diabetes (EUROASPIRE IV) Registry. *Int J Cardiol.* 2020; 300: 7–13. DOI: https://doi.org/10.1016/j.ijcard.2019.09.015

33. **Kotseva K, Wood D, De Bacquer D.** Determinants of participation and risk factor control according to attendance in cardiac rehabilitation programmes in coronary patients in Europe: EUROASPIRE IV survey. *Eur J Prev Cardiol.* 2018; 25(12): 1242–1251. DOI: https://doi.org/10.1177/2047487318781359

34. **Taylor RS, Dalal HM, McDonagh STJ.** The role of cardiac rehabilitation in improving cardiovascular outcomes. Nature Reviews Cardiology. *Nature Research.* 2022; 19: 180–194. DOI: https://doi.org/10.1038/s41569-021-00611-7

35. **Ohm J, Skoglund PH, Häbel H, Sundström J, Hambraeus K, Jernberg T,** et al. Association of socioeconomic status with risk factor target achievements and use of secondary prevention after myocardial infarction. *JAMA Netw Open.* 2021; 4(3): e211129. DOI: https://doi.org/10.1001/jamanetworkopen.2021.1129

36. **Sun EY, Jadotte YT, Halperin W.** Disparities in cardiac rehabilitation participation in the United States: A systematic review and meta-analysis. *Journal of Cardiopulmonary Rehabilitation and Prevention.* Lippincott Williams and Wilkins. 2017; 37: 2–10. DOI: https://doi.org/10.1097/HCR.0000000000000203

37. **Abreu A, Pesah E, Supervia M, Turk-Adawi K, Bjarnason-Wehrens B, Lopez-Jimenez F,** et al. Cardiac rehabilitation availability and delivery in Europe: How does it differ by region and compare with other high-income countries? Endorsed by the European Association of Preventive Cardiology. *Eur J Prev Cardiol.* 2019; 26(11): 1131–1146. DOI: https://doi.org/10.1177/2047487319827453

38. **Turk-Adawi K, Supervia M, Ghisi G, Cuenza L, Yeo TJ, Chen SY,** et al. The impact of ICCPR's Global Audit of Cardiac Rehabilitation: where are we now and where do we need to go? *EClinicalMedicine.* 2023; 61: 102092. DOI: https://doi.org/10.1016/j.eclinm.2023.102092

39. **Ghisi GL de M, Taylor RS, Seron P, Grace SL.** Factors hindering cardiac rehabilitation in low- and middle-income countries, by level and setting. *J Cardiopulm Rehabil Prev.* 2023; 43(2): 143–144. DOI: https://doi.org/10.1097/HCR.0000000000000774

40. **Gabulova R, Marzà-Florensa A, Rahimov U, Isayeva M, Alasgarli S, Musayeva A,** et al. Risk factors in cardiovascular patients: Challenges and opportunities to improve secondary prevention. *World J Cardiol.* 2023; 15(7): 342–353. DOI: https://doi.org/10.4330/wjc.v15.i7.342

41. **World Heart Report 2023: Confronting the World's Number One Killer.** Geneva, Switzerland. *World Heart Federation.* 2023.